about
Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialAlcohol consumption and risk of leukemia: A multicenter case-control studyEtiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes ProjectPhase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast CancerIntra-operative radiological margins assessment in conservative treatment for non-palpable DCIS: correlation to pathological examination and re-excision rate.Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experienceA phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on job titles.Chronic lymphocytic leukaemias and non-Hodgkin's lymphomas by histological type in farming-animal breeding workers: a population case-control study based on a priori exposure matrices.High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials.Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patientsClinical and genetic factors related to cancer-induced bone pain and bone pain relief.Urine telomerase: an important marker in the diagnosis of bladder cancer.Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stoolDoes the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?Delayed infection, family size and malignant lymphomas.Haematopoietic cancer and medical history: a multicentre case control study.Lymph node pick up by separate stations: Option or necessity.Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of deliriumProspective comparison of prognostic scores in palliative care cancer populations.Hormone replacement treatment and breast cancer risk: a cooperative Italian study.Inverse probability weighting to estimate causal effect of a singular phase in a multiphase randomized clinical trial for multiple myeloma.Setting up a community-based cervical screening service in a low-income country: a pilot study from north-western Tanzania.Transbronchial biopsy is useful in predicting UIP pattern.Appropriate use of tumour biomarkers for treatment with innovative drugs: A retrospective study.Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.Role of biological markers in the clinical outcome of colon cancer.Delayed infection, late tonsillectomy or adenoidectomy and adult leukaemia: a case-control studyeNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.Implementing an evidence-based computerized decision support system linked to electronic health records to improve care for cancer patients: the ONCO-CODES study protocol for a randomized controlled trial.Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.Palliative sedation in end-of-life care and survival: a systematic review.Palliative sedation in end-of-life care.Palliative sedation for intolerable suffering.Reproducibility of an Italian food frequency questionnaire for cancer studies: results for specific food items.New requirements for phase I trials: a challenge for Italian clinical research.
P50
Q24804008-B56E0ACE-93A9-4FD2-BD7E-9E311C9704B2Q24807379-41CFE348-E838-4A67-A003-573B27BCA978Q28258761-5EF0EB88-DEAC-4CF6-BB45-8815B0057A2DQ28393769-2ECAE0DF-78C9-4635-81A4-C1E1F166FE79Q28555102-F5C57AD3-9E87-4ABC-B874-255E2496DA9DQ30540225-8F0C91E3-B10B-4875-8138-57EDEC8A5BE5Q33237182-6F56C02C-D493-44E1-A7DD-7D18106863DCQ33395752-0ACA9D67-5D9B-4C20-833D-04E29866508EQ33600072-E48DACC3-7D51-4137-878C-8C2157DA46FEQ33683918-0C93B013-722D-42BC-BB7C-FFADA7B97AD4Q33819116-0851CC8F-4139-4B33-A861-DE2C5FE04D76Q33820121-B8241FB0-4CED-4459-9597-570E8B57B4B2Q33945113-851AFABC-1BCF-47A9-B39B-71CE6354D1D3Q34005121-7D436EF7-787C-41E3-A117-FBB3C83D094CQ34641014-C293CED7-7B48-42FF-8010-CFD082527CF7Q34770052-187BC2DE-7970-4995-89A3-5772661CABE1Q34928368-85357E45-C8A3-4662-BCA6-5531A834052BQ35384490-41A5707F-BE3E-414A-B167-AF8BC429CA7AQ35400803-4ABCA2CA-C4DB-4779-BBC4-C7501895AEB1Q35402136-D428E5FB-7F2F-4E14-ADF1-96959E59CCB3Q35626662-2338622A-D45B-44D9-91FE-D1821BC6F02CQ35642409-5CDBF87D-C209-4E73-AF57-E7B750CFC0E8Q35863918-7FCD6756-476D-4D79-AD90-B10E7579CAF3Q36082003-B5BBFB8F-92BC-4EC1-8D05-065E5467BCEDQ36187756-ECF3C767-EBF5-4832-94C4-73B4E25959C2Q36351479-8A98D449-B061-4352-86A5-A6C7E182C221Q36402285-3A5A0CA0-48E2-49C5-84A4-B0563F84FC15Q36502531-002F33CF-FE30-4FC4-A00D-3A2EE0352A7CQ36610731-50C959E1-4380-4AC6-AF7C-656BAEE22A13Q36646148-58A5F1D2-7DF7-4EE5-94BC-CBB844A6B9A9Q36647871-C8C430BA-2C47-4E92-A7B2-B99B750259A4Q37317462-1A63B716-E0BE-4461-86F1-6468C2103ECDQ37440138-363E7790-1DA9-4471-BC1C-C26EF776B5BAQ37458009-61609A7E-0C21-43C0-912C-7F6EFDEAC5C7Q37861447-EB689AF1-FA48-4C01-B27B-2E1ED47C3017Q37993047-94BB02FE-07D3-4BF3-BAA2-C81ADC56E56FQ38105964-5EAEB674-3C38-42A4-88CE-9B8541226D90Q38211563-6C03C947-35F3-4A49-971D-54CAE4F4DC2CQ38569340-DE2F1B70-EA6F-4BFE-B0CC-84FAF9659CF7Q38643895-898A163F-A0D8-48F5-802B-FEB72C106CDD
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Oriana Nanni
@ast
Oriana Nanni
@en
Oriana Nanni
@es
Oriana Nanni
@nl
Oriana Nanni
@sl
type
label
Oriana Nanni
@ast
Oriana Nanni
@en
Oriana Nanni
@es
Oriana Nanni
@nl
Oriana Nanni
@sl
prefLabel
Oriana Nanni
@ast
Oriana Nanni
@en
Oriana Nanni
@es
Oriana Nanni
@nl
Oriana Nanni
@sl
P1053
K-3240-2016
P106
P1153
7006824406
P21
P31
P3829
P496
0000-0001-7338-2896